Contact

Level Trailhead 43 Home About Services Trial Tracker Safety & Risks Regulatory Timeline Contact Research context · September 30, 2026 Ibogaine Clinical Trial News Today: Latest Updates Ibogaine research has entered a more consequential but still preliminary phase. The clearest signal is not a proven treatment: it is a shift toward monitored human research, defined safety rules, and carefully scoped questions. Level Trailhead 43 is an independent resource on ibogaine research, safety, and clinical trials. It distinguishes early research from established care. A useful distinction for every headline: a study authorization is not fda approval, and an investigational protocol is not routine care. The present moment What is moving forward, and what is not As of late September 2026, ibogaine remains investigational, unapproved, and medically high-risk. Yet current research includes early human trials of noribogaine, staged work for opioid dependence, and planned protocols for neurological recovery. A registered federal study record helps separate a formal protocol from claims made outside clinical settings. The practical question is whether clinical research can measure therapeutic potential while protecting participants from known cardiac and interaction risks. This is a validation-of-research year, not a validation-of-treatment year. 01 Early human work Phase 1 trials are designed to characterize dose response, pharmacokinetics, and patient safety. They do not establish that an experimental treatment works for a substance use disorder. 02 Focused questions Phase 2 trials can examine opioid dependence, withdrawal symptoms, alcohol use disorder, or neurological effects in more defined participant groups and controlled environment protocols. 03 Evidence still needed Long-term outcomes, replication, comparisons with treatment options, and a clearer safety profile remain essential before fda approval could be considered. Mechanism under study A compound, a metabolite, an

Contact

How to reach us